Corvus Pharmaceuticals, Inc. — Director's Dealing 2017

Dec 15, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2017-12-13

Reporting Person: Hunt Daniel W. (SVP, Chief Business Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-13	Stock Option (Right to Buy)	$10.60	A	200000	Acquired	2027-12-13	Common Stock (200000)	Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to twenty-five percent (25%) of the shares subject to the option on November 27, 2018 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.